A BILL 
To amend subsection (q) of section 505 of the Federal Food, 
Drug, and Cosmetic Act to clarify the process for deny-
ing certain petitions whose primary purpose is to delay 
the approval of an application submitted under sub-
section (b)(2) or (j) of such section 505, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Stop The Overuse of 
4
Petitions and Get Affordable Medicines to Enter Soon Act 
5
of 2021’’ or the ‘‘STOP GAMES Act of 2021’’. 
6
02:42 Jun 08, 2021
H2843
2 
•HR 2843 IH
SEC. 2. DENIAL OF PETITIONS WHOSE PRIMARY PURPOSE 
1
IS TO DELAY APPROVAL OF CERTAIN APPLI-
2
CATIONS. 
3
(a) IN GENERAL.—Subparagraph (E) of section 
4
505(q)(1) of the Federal Food, Drug, and Cosmetic Act 
5
(21 U.S.C. 355(q)(1)) is amended to read as follows: 
6
‘‘(E) DENIAL
BASED
ON
INTENT
TO 
7
DELAY.— 
8
‘‘(i) IN
GENERAL.—If the Secretary 
9
determines that a petition or a supplement 
10
to the petition was submitted with the pri-
11
mary purpose of delaying the approval of 
12
an application or the petition does not on 
13
its face raise valid scientific or regulatory 
14
issues, the Secretary may deny the petition 
15
at any point based on such determination. 
16
‘‘(ii) FACTORS.—The Secretary may 
17
issue guidance to describe the factors that 
18
will be used to determine under this sub-
19
paragraph whether a petition is submitted 
20
with the primary purpose of delaying the 
21
approval of an application. Such factors 
22
shall include the following: 
23
‘‘(I) Submission of a petition 
24
where it appears, based on the date 
25
that relevant information relied upon 
26
02:42 Jun 08, 2021
H2843
3 
•HR 2843 IH
in the petition became known to the 
1
petitioner (or reasonably should have 
2
been known to the petitioner), that 
3
the petitioner has taken an unreason-
4
able length of time to submit the peti-
5
tion. 
6
‘‘(II) Submission of multiple or 
7
serial petitions raising issues that rea-
8
sonably could have been known to the 
9
petitioner at the time of submission of 
10
the earlier petition or petitions. 
11
‘‘(III) Submission of a petition 
12
close in time to a known, first date 
13
upon which an application under sub-
14
section (b)(2) or (j) of this section or 
15
under section 351(k) of the Public 
16
Health Service Act could be approved 
17
(such as submission close in time to 
18
the expiration of a blocking patent or 
19
exclusivity). 
20
‘‘(IV) Submission of a petition 
21
without any data or information in 
22
support of the scientific positions set 
23
forth in the petition. 
24
02:42 Jun 08, 2021
H2843
4 
•HR 2843 IH
‘‘(V) Submission of a petition 
1
raising the same or substantially simi-
2
lar issues as a prior petition to which 
3
the Food and Drug Administration 
4
has already substantively responded, 
5
particularly where the subsequent sub-
6
mission closely follows in time the ear-
7
lier response. 
8
‘‘(VI) Submission of a petition 
9
concerning standards for approval of 
10
a drug product for which— 
11
‘‘(aa) the Food and Drug 
12
Administration has provided an 
13
opportunity 
for 
public 
input 
14
(such as when the Food and 
15
Drug Administration has issued 
16
draft or final product-specific 
17
guidance applicable to the drug 
18
product); and 
19
‘‘(bb) the petitioner has not 
20
provided comment other than 
21
through the petition. 
22
‘‘(VII) Submission of a petition 
23
requesting that other applicants must 
24
meet standards for testing, data, or 
25
02:42 Jun 08, 2021
H2843
5 
•HR 2843 IH
labeling for their products that are 
1
more onerous or rigorous than the 
2
standards applicable to the applicable 
3
listed drug or the petitioner’s version 
4
of the same product. 
5
‘‘(VIII) Other relevant consider-
6
ations, including the history of the pe-
7
titioner with the Food and Drug Ad-
8
ministration (such as whether the pe-
9
titioner has a history of submitting 
10
petitions which the Food and Drug 
11
Administration has determined were 
12
submitted with the primary purpose of 
13
delay). 
14
‘‘(iii) REFERRAL TO FTC.—If the Sec-
15
retary determines that a petition has been 
16
submitted with the primary purpose of de-
17
laying the approval of an application, as 
18
described in clause (i), the Secretary shall 
19
refer the matter to the Federal Trade 
20
Commission.’’. 
21
(b) DEADLINE FOR SUBMISSION OF PETITIONS.— 
22
(1) 
DEADLINE.—Clause 
(i) 
of 
section 
23
505(q)(1)(A) of the Federal Food, Drug, and Cos-
24
02:42 Jun 08, 2021
H2843
6 
•HR 2843 IH
metic Act (21 U.S.C. 355(q)(1)(A)) is amended to 
1
read as follows: 
2
‘‘(i) the request is in writing, is a pe-
3
tition submitted to the Secretary pursuant 
4
to section 10.30, 10.31, or 10.35 of title 
5
21, Code of Federal Regulations (or any 
6
successor regulations), and is submitted 
7
not later than 60 days after the informa-
8
tion upon which the petition is based first 
9
became known to the party on whose be-
10
half the petition is submitted; and’’. 
11
(2) CERTIFICATION.—Section 505(q)(1)(H) of 
12
the Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 355(q)(1)) is amended by striking ‘‘I further 
14
certify that the information upon which I have based 
15
the action requested herein first became known to 
16
the party on whose behalf this petition is submitted 
17
on or about the following date: llll.’’ and in-
18
serting ‘‘I further certify that the information upon 
19
which I have based the action requested herein first 
20
became known to the party on whose behalf this pe-
21
tition is submitted on or about llll, which 
22
date was not more than 60 days before the date of 
23
submitting this petition.’’. 
24
02:42 Jun 08, 2021
H2843
7 
•HR 2843 IH
(c) REPORTING TO CONGRESS.—Section 505(q)(3) of 
1
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
2
355(q)(3)) is amended— 
3
(1) in the matter before subparagraph (A), by 
4
striking ‘‘specifies’’; 
5
(2) in subparagraphs (A), (B), (C), and (D), by 
6
striking ‘‘the number’’ and inserting ‘‘specifies the 
7
number’’; 
8
(3) in subparagraph (C), by striking ‘‘and’’ at 
9
the end; 
10
(4) in subparagraph (D), by striking the period 
11
at the end and inserting ‘‘; and’’; and 
12
(5) by adding at the end the following: 
13
‘‘(E)(i) lists each petition submitted during 
14
such period and, for each, identifies the peti-
15
tioner; 
16
‘‘(ii) quantifies the time and resources ex-
17
pended on each such petition; 
18
‘‘(iii) states the timing of the petition rel-
19
ative to the expiration date of the patents speci-
20
fied in the pending application in the certifi-
21
cation 
under 
subsection 
(b)(2)(A) 
or 
22
(j)(2)(A)(vii), as applicable; 
23
‘‘(iv) quantifies the delay, if any, caused by 
24
any such petition on the approval of any appli-
25
02:42 Jun 08, 2021
H2843
8 
•HR 2843 IH
cation submitted under subsection (b)(2) or (j), 
1
including a description of how any such delay is 
2
calculated and an estimate of when any delayed 
3
approval would have been granted absent the 
4
petition; and 
5
‘‘(v) in cases in which a pending applica-
6
tion and a petition with respect to such pending 
7
application are disposed of on the same or near-
8
ly the same date, states when the Food and 
9
Drug Administration would have disposed of 
10
the pending application absent the petition.’’. 
11
Æ 
02:42 Jun 08, 2021
H2843
